CureVac AG is a biopharmaceutical company that specializes in the development of mRNA-based vaccines and therapies. The company focuses on leveraging its proprietary mRNA technology to address various diseases, including oncological and infectious diseases, as well as rare diseases.

Cure Ventures is a venture capital firm focusing on company formation around groundbreaking curative technologies.

Cure Ventures harnesses our team's skills and decades of company-building experience to create innovative companies that aim to eradicate diseases by focusing on de novo company formation built around bold ideas and visionary entrepreneurs. 

We provide the right level of human and financial capital that is required at each stage of the company's life. We seek to build great companies around pioneering scientific solutions with strong intellectual property positions. The Cure Ventures team focuses on disruptive technologies that target high unmet patient needs.

The optimal company build will exhibit a clear genetic validation, substantiated and rigorously derived scientific data, the provenance of a distinguished scientific laboratory, biology with mechanistic clarity, multiple commercial applications, large uncrowded markets, expedited clinical routes, string partnering interest from large pharmaceutical companies, and an articulable oath to an exit.

Cure Ventures

Cure Ventures is proud to call #Boston home to our newly launched #venturecapital firm. We recently talked with Jonathan Saltzman at Boston Globe Media about our plans to help build new #lifescience and #biotech companies, some of which may be in the Boston area! Read the full article below:

Our founding partners recently sat down with Brian Gormley at The Wall Street Journal to discuss Cure Ventures’ inaugural fund launch and our team’s unique investment approach. Read the full article below. #venturecapital #lifescience #boston

Today we announced the close at the targeted hard cap of $350 million for our inaugural fund. The fund is led by managing partners Richard Lim, David Fallace, and Lou Tartaglia and will build new life science and biotech companies, primarily focused on the development of innovative and impactful therapeutics.
 
Our unique approach embraces genetic validation as part of an iterative process to guide a drug through development, increasing the probability of success and mitigating the cost of failure. Embedded Cure operators will work alongside portfolio company founders to drive day-to-day decision making. We leverage a seed funding model, allowing for important de-risking activities and setting companies up for success in the clinic and beyond. 
 
We founded Cure with a grand ambition: to eradicate life-debilitating and life-ending diseases with curative technologies. We know it is people who drive the development of therapeutics that change patients’ lives, not capital. This is why we are committed to continuously interrogating and validating technology to find the best path forward in collaboration with founders.

Read the press release here: https://lnkd.in/g6hDShiX

#venturecapital #lifescience #biotech

COM:CUREVC

CureVac AG

Analysis Not Available